Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.

ABSTRACT:

Objectives

To identify switch modalities used when initiating second- or third-line anagrelide for essential thrombocythemia (ET), assess whether anagrelide is initiated consistently with Summary of Product Characteristics (SPC) recommendations, and determine whether different observed switch regimens have any relationship with maintenance, platelet response, or tolerability.

Methods

This observational study was conducted across 43 centers in France. High-risk patients (>60 yr of age and/or history of thrombosis and/or platelet count >1000 × 10(9) /L) with ET starting second- or third-line anagrelide therapy were identified and monitored for 6 months.

Results

A total of 177 patients were enrolled. The SPC-recommended starting dose (1 mg/d) was used in 52.6% of patient

SUBMITTER: Rey J 

PROVIDER: S-EPMC4232889 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature